Shorts

New treatment options complicate BCG-unresponsive NMIBC care

Why female sexual health is often overlooked in bladder cancer care

How APPs can expand access to clinical trials

What policymakers must do to preserve patient choice

Why the bladder diary matters in nocturia workup

3 actionable steps to improve PSMA-PET access

Site-neutral payment and the future of community urology

Reassessing goals of care throughout cancer treatment

Neoadjuvant therapy before prostatectomy: Assessing functional outcomes

How unequal PSMA-PET access may affect prostate cancer care

What a positive NeoBLAST trial would mean for MIBC care

Why independent urology practices face growing pressure

The long-term cost question behind OAB drug selection

How to spot patients chasing a product, not a diagnosis

How NeoBLAST defines and confirms complete response

Considering the practical benefits of intraoperative chemotherapy at nephroureterectomy

What the evidence says on penile cancer margin management

4 steps to implementing a rapid access model for elevated PSA

The ambition behind the first MIBC surveillance RCT

Why GLP-1 and TRT combinations require careful sequencing

How urologists can support the State of Men’s Health Act

Streamlining elevated PSA evaluation through telehealth

Selecting patients for bladder-sparing surveillance

Separating TRT evidence from marketing in clinical practice

Erectile dysfunction and cardiovascular health: An opportunity for urologists

Why urology and REI collaboration needs to start earlier

Nerve-sparing prostatectomy: Surgical gestures linked to erectile function recovery

Nocturia in older adults: Understanding its clinical significance

The case for permanent Medicare payment reform in urology

The UroOnc Minute: Emphasizing cribriform and IDC reporting in prostate cancer